Clinical trials: Diabetes Type I
Diabetes Mellitus, Type 1
INTERPRET - International Report on Routine Practice of Sensor-enabled Pump Therapy
The aim of the project is to document the international routine practice in sensor usage in patients treated with sensor-augmented pump therapy and to assess which variables (e.g.
- Trial name
- NCT00790088
- Where
- 26 sites in Austria, Belgium and 12 more
- Volunteers
- 274 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
In an earlier Phase 1/2 clinical trial using the Edmonton Protocol of steroid free immunosuppression, investigators at University of Illinois at Chicago (UIC) demonstrated the safety of islet preparation, iset transplantation…
- Trial name
- NCT00679042
- Testing
- Islets of Langerhans transplantation
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- CellTrans Inc.
Diabetes Mellitus, Type 1
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
- Trial name
- CATT1 (NCT06334133)
- Testing
- Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- vTv Therapeutics
Diabetes Mellitus, Diabetes Mellitus, Type 1
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
This study is conducted in Europe and Asia. The purpose of the study (Diabetes Pregnancy Registry) is to evaluate the safety of treatment with insulin detemir in pregnant women with diabetes mellitus.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01892319
- Testing
- insulin detemir, other injectable antidiabetic treatment regimens
- Where
- 93 sites in Croatia, Finland and 14 more
- Volunteers
- 2,446 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity.
- Conditions
- Diabetes Mellitus, Type 1, Overweight, Obesity
- Trial name
- NCT07803744
- Testing
- Tirzepatide, Acetaminophen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus
This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicentre study of 52 weeks treatment duration.
- Trial name
- NCT02284009
- Testing
- Albiglutide weekly injection, Insulin
- Where
- 32 sites in France, Germany and 3 more
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1, Type 1 Diabetes
"FEXIS": (Feasibility of an Extended Wear CSII Set in Participants With T1DM)
Over 1 million patients globally currently manage their Type 1 Diabetes mellitus using continuous subcutaneous insulin infusion with an infusion set that needs to be changed every 3 days.
- Conditions
- Diabetes Mellitus, Type 1, Type 1 Diabetes, Type 1 Diabetes Mellitus, Diabetes Mellitus, Insulin-Dependent, 1
- Trial name
- FEXIS (NCT04503564)
- Testing
- coil-reinforced soft polymer indwelling cannula
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Capillary Biomedical, Inc.
Type 1 Diabetes
ADvanced Hybrid Closed Loop Study in Adult Population With Type 1 Diabetes
The purpose of this study evaluate the safety and efficacy of the Advanced Hybrid Closed Loop (AHCL) system in sub-optimally controlled patients with T1D, in comparison with Multiple Daily Injection (MDI) therapy with Flash…
- Trial name
- ADAPT (NCT04235504)
- Testing
- MDI, AHCL
- Where
- 14 sites in France, Germany and 1 more
- Volunteers
- 122 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV). ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects.
- Trial name
- ZYD1 (NCT01972893)
- Testing
- ZYD1
- Where
- India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Feasibility Study of Blood Glucose Monitoring With the Non-invasive Medical Device D-Base
This study aims to evaluate the feasibility of monitoring the blood glucose values by measuring the glucose in the interstitial fluid of the skin on the wrist of subjects with diabetes mellitus type 1 and 2.
- Trial name
- NCT05169034
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Diamontech AG
Type 1 Diabetes Mellitus
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
The primary purpose of participation in this study is to compare the safety and efficacy of different dosing schedules of LY2605541 and how different dosing schedules of LY2605541 affect Hemoglobin A1c (HbA1c).
- Trial name
- IMAGINE 7 (NCT01792284)
- Testing
- LY2605541, Insulin Lispro
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 212 people
- Sponsor
- Eli Lilly and Company
Gastroparesis
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis
The purpose of this study is to assess the pharmacodynamic effects (gastric emptying), safety, tolerability, and pharmacokinetics of single doses of GSK962040 in Type 1 diabetic patients with gastroparesis.
- Trial name
- NCT00861809
- Testing
- GSK962040 25 mg, GSK962040 50 mg, GSK962040 1250 mg
- Where
- 2 sites in Belgium, Sweden
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 1
Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles
This trial is conducted in Europe. The primary aim of this clinical trial is to locate and compare simulated insulin injections (injections of sterile atmospheric air) in normal weight and obese patients with diabetes mellitus.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00871416
- Testing
- NovoFine® needle 6 mm, NovoFine® needle 12 mm
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects
This study is conducted in Asia. The aim of this observational study is to evaluate the side effects profile and benefits of using intravenous insulin aspart infusion in hospitalised subjects under normal clinical practice…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00700648
- Testing
- insulin aspart
- Where
- India
- Volunteers
- 3,024 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Type 2 Diabetes
A Study of LY8888AX in Participants Using a Connected Insulin Management Platform
The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
- Trial name
- NCT05893797
- Testing
- Insulin Lispro, Tempo Smart Button, Dexcom G6 CGM
- Where
- 9 sites in France
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Non-Insulin-Dependent Diabetes Mellitus
GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients
This is a study to compare the safety, blood concentrations, and effects of GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.
- Trial name
- NCT00291356
- Testing
- GSK189075 oral tablets, GW869682 oral tablets
- Where
- 3 sites in United States, Germany
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump
This study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes LY900014, a new blood sugar lowering insulin, and its effect on blood sugar levels when it is delivered via an…
- Trial name
- NCT03056456
- Testing
- LY900014, Insulin Lispro (Humalog)
- Where
- 2 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in…
- Trial name
- NCT01194245
- Testing
- Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart
- Where
- 19 sites in United States
- Volunteers
- 135 people
- Sponsor
- Halozyme Therapeutics
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this clinical trial is to evaluate the variability in the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- NCT00961324
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes
This is a phase 3, open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected pre-meal insulin in non-smoking patients with type 1 diabetes.
- Trial name
- NCT00127634
- Testing
- Human Insulin Inhalation Powder, Injectable Insulin, Insulin Glargine
- Where
- 61 sites in United States, Belgium and 4 more
- Volunteers
- 385 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.